Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System
Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.
Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript
Nyxoah SA ( NYXH ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Pearson Dennis Olivier Taelman - CEO & Executive Director John Landry - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Adam Maeder - Piper Sandler & Co., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Paige Chamberlain - Wolfe Research, LLC Presentation Operator Good day, and thank you for standing by.
Nyxoah SA (NYXH) Reports Q3 Loss, Beats Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to a loss of $0.55 per share a year ago.
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nyxoah Expands in the Middle East to Provide Wider Access to Genio
NYXH expands in the Middle East after Abu Dhabi's first Genio implant, aiming to broaden access for OSA patients.
Nyxoah SA (NYXH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Nyxoah SA (NASDAQ:NYXH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Olivier Taelman - CEO & Executive Director Presentation Unknown Analyst Excellent. Thank you, everyone, for joining us.
Nyxoah: High-Risk High-Reward Medtech To Own
Nyxoah's Genio system received FDA approval, unlocking access to the US market and validating its innovative, patient-friendly OSA treatment. Recent earnings show strong revenue growth but continued losses as Nyxoah invests heavily in US commercialization and expansion efforts. Key risks include rising debt, dilution, ongoing patent litigation, and high competition, but GLP-1 drugs pose less threat than initially feared.
Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript
Nyxoah SA (NASDAQ:NYXH ) Q2 2025 Earnings Conference Call August 18, 2025 4:30 PM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO & Executive Director Pearson Dennis - Corporate Participant Conference Call Participants David Kenneth Rescott - Robert W. Baird & Co. Incorporated, Research Division Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division Junwoo Park - Cantor Fitzgerald & Co., Research Division Kyle Edward Winborne - Piper Sandler & Co., Research Division Michael K.
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.45 per share a year ago.
Nyxoah SA (NYXH) Q4 2024 Earnings Call Transcript
Nyxoah SA (NASDAQ:NYXH ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO Conference Call Participants Adam Maeder - Piper Sandler Jon Block - Stifel Matthew Park - Cantor Fitzgerald Suraj Kalia - Oppenheimer & Co. David Rescott - Baird Paige Chamberlain - Wolfe Research Operator Hello, and welcome to Nyxoah Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.41 per share a year ago.
